Dr. Fitzpatrick added, “We plan to conduct specialized studies to understand more than we currently do about the drug’s mechanism of action. For example, how does the drug prevent fractures at different sites? What is the bone microarchitecture in those sites?”
“Currently, abaloparatide is under review by regulatory agencies worldwide,” she says. “A new drug application was submitted to the FDA on March 30.”